Rocket Doctor AI pitches microcap investors in Florida: AI's healthcare hype is trading on the market too

By Zendoric · October 1, 2026.

The facts are minimal. Rocket Doctor AI Inc., a Canadian company listed on the Canadian Securities Exchange (CSE:AIDR), on the US over-the-counter market (OTC:AIRDF) and in Frankfurt, has announced that its CEO, Dr. Essam Hamza, will present on October 7 at the National Investment Banking Association's (NIBA) 153rd investment conference in Fort Lauderdale, Florida. According to the company itself, the presentation will review "recent milestones" and its "growth strategy," though the release does not put a single concrete figure on any of those milestones.

What the release does provide is the usual product sheet: the company says it combines Rocket Doctor, a digital health platform and marketplace, with the Global Library of Medicine (GLM), a clinical decision support system it describes as "clinically validated" and developed with input from "hundreds of physicians." It claims to have helped more than 350 doctors handle over 800,000 patient visits, with a focus on rural communities in Canada and on patients in the public Medicaid and Medicare programs in the United States. These are the company's own figures: the release cites no study, audit or independent third party to back them up.

It is worth reading the context before the headline. NIBA is a non-profit association that has spent nearly 50 years organizing gatherings for the micro-cap and small-cap investment community, that is, listed companies with very small market capitalizations. The text itself was distributed by B2i Digital, an investor relations firm that features Rocket Doctor AI as a "featured company" in its client portfolio, and it comes with the standard legal disclaimers about "forward-looking statements" required by Canadian securities rules. In short: this is not a clinical or technological story, it is an investor relations notice packaged as an AI and health news item.

That distinction matters because in healthcare the scoreboard that really counts is not the capital-markets narrative but clinical evidence: trials, regulatory approvals, patient outcomes measured by third parties. Labeling a product "AI" and presenting it to micro-cap investors is, today, a common route for small listed companies to gain visibility and funding, taking advantage of the term's appeal in the market; that does not automatically make it a medical breakthrough, nor does it discredit it, it simply has not been demonstrated here. As sector context, this is precisely the gap to watch in digital health: AI's long-term promise —more accurate diagnoses, expanded access for underserved communities, more physician time for the patient— is real and deserves following, but it only holds up with auditable clinical data, not with stock-market releases. Until Rocket Doctor AI publishes that data, the only verifiable thing in this story is that its CEO is going to give a talk to investors in Florida.